Patient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-γ Responsive Pathway

Kathrin Haake1, Anna-Lena Neehus1,2,3, Theresa Buchegger1

  • 1REBIRTH Cluster of Excellence, Institute of Experimental Hematology, Hannover Medical School (MHH), 30625 Hannover, Germany.

Cells
|February 26, 2020
PubMed

Insights

We developed a novel platform using patient-derived stem cells to model interferon-gamma (IFN-γ) related diseases. This system effectively studied macrophage dysfunction in Mendelian Susceptibility to Mycobacterial Disease (MSMD) patients.

Area of Science:

  • Immunology
  • Genetics
  • Stem Cell Biology

Background:

  • Interferon gamma (IFN-γ) is a key macrophage activator, crucial for immunity.
  • Inborn errors in IFN-γ immunity lead to Mendelian Susceptibility to Mycobacterial Disease (MSMD).
  • Macrophages from MSMD patients have been understudied.

Purpose of the Study:

  • To establish a disease modeling platform for IFN-γ related pathologies.
  • To investigate macrophage function in patients with genetic IFN-γ pathway deficiencies using induced pluripotent stem cells (iPSCs).

Main Methods:

  • Generation of macrophages from iPSCs of patients with deficiencies in IFN-γR1, IFN-γR2, and STAT1.
  • Assessment of both IFN-γ-independent (e.g., phagocytosis) and IFN-γ-dependent macrophage functions.
  • Challenging iPSC-derived macrophages with Bacillus Calmette-Guérin to evaluate mycobacterial growth control.

Main Results:

  • Patient-derived macrophages exhibited normal morphology and IFN-γ-independent functions.
  • Complete IFN-γR2 and STAT1 deficiencies caused the most severe defects in IFN-γ-dependent pathways.
  • Partial deficiencies allowed residual downstream target induction but failed to control mycobacterial growth.

Conclusions:

  • A novel iPSC-based macrophage model effectively recapitulates IFN-γ pathway defects.
  • This platform is valuable for studying macrophage roles in MSMD and other IFN-γ-related disorders.
  • Understanding these genetic defects is crucial for developing therapeutic strategies for mycobacterial diseases.